VACC · Vaccitech PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $14.97M | $802.0K | $44.70M | $4.82M |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| R&D | $25.56M | $42.24M | $44.87M | $42.35M | $14.39M |
| SG&A | $40.83M | $29.67M | $39.84M | $6.39M | $10.48M |
| Total Operating Expenses | $71.06M | $84.11M | $84.72M | $48.74M | $24.87M |
| D&A | $5.84M | $5.80M | $5.43M | $4.32M | $208.0K |
| Operating Income | ($70.56M) | ($67.97M) | ($83.91M) | ($4.04M) | ($20.05M) |
| Interest Expense | $51.0K | $53.0K | $28.0K | $19.0K | $3.60M |
| Income Tax | ($175.0K) | ($44.0K) | ($3.08M) | ($4.47M) | $95.0K |
| Net Income | ($66.43M) | ($61.07M) | ($73.35M) | $5.34M | ($17.71M) |
| EPS - Basic | ($1.64) | ($1.55) | ($1.91) | $0.14 | ($2.24) |
| EPS - Diluted | ($1.64) | ($1.55) | ($1.91) | $0.14 | ($2.24) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $70.46M | $110.66M | $142.09M | $194.38M | $214.05M |
| Accounts Receivable | - | - | - | $323.0K | $20.0K |
| Inventory | - | - | - | - | - |
| Accounts Payable | $350.0K | $2.47M | $1.60M | $3.75M | $2.42M |
| Current Assets | $77.79M | $125.74M | $156.91M | $213.04M | $226.76M |
| Total Assets | $98.17M | $160.33M | $214.51M | $270.20M | $280.71M |
| Current Liabilities | $10.02M | $15.66M | $12.60M | $12.24M | $11.16M |
| Long-term Debt | - | - | - | - | - |
| Total Liabilities | $23.88M | $30.19M | $27.51M | $27.00M | $28.15M |
| Stockholders' Equity | $74.21M | $130.03M | $186.78M | $242.90M | $252.56M |
| Retained Earnings | ($304.09M) | ($237.66M) | ($176.59M) | ($103.24M) | ($108.58M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | ($47.98M) | ($28.94M) | ($50.92M) | ($14.43M) | ($11.03M) |
| Investing Cash Flow | $416.0K | ($892.0K) | ($5.41M) | ($5.75M) | ($293.0K) |
| Financing Cash Flow | $2.0K | $2.16M | $1.87M | $325.0K | $41.44M |
| CapEx | $37.0K | $892.0K | $5.41M | $6.14M | $293.0K |
| Free Cash Flow | ($48.02M) | ($29.83M) | ($56.34M) | ($20.57M) | ($11.32M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | - | - | - | - | - |
| Operating margin | - | -454.1% | -10463.1% | -9.0% | -415.8% |
| EBITDA margin | - | -415.3% | -9786.2% | 0.6% | -411.5% |
| Net margin | - | -408.0% | -9145.5% | 11.9% | -367.3% |
| Free cash flow margin | - | -199.3% | -7024.7% | -46.0% | -234.8% |
| FCF / Net income | 0.72 | 0.49 | 0.77 | -3.85 | 0.64 |
| R&D / Revenue | - | 282.2% | 5595.3% | 94.7% | 298.4% |
| SG&A / Revenue | - | 198.2% | 4967.8% | 14.3% | 217.4% |
| Effective tax rate | - | - | - | -513.3% | - |
| Return on assets | -67.7% | -38.1% | -34.2% | 2.0% | -6.3% |
| Return on equity | -89.5% | -47.0% | -39.3% | 2.2% | -7.0% |
| Return on invested capital | - | - | - | - | - |
| Liquidity | |||||
| Current ratio | 7.77 | 8.03 | 12.45 | 17.40 | 20.32 |
| Quick ratio | 7.77 | 8.03 | 12.45 | 17.40 | 20.32 |
| Cash ratio | 7.03 | 7.07 | 11.28 | 15.88 | 19.18 |
| Leverage | |||||
| Debt / Equity | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Interest coverage | -1383.4x | -1282.5x | -2996.9x | -212.7x | -5.6x |
| Equity multiplier | 1.32 | 1.23 | 1.15 | 1.11 | 1.11 |
| Liabilities / Assets | 0.24 | 0.19 | 0.13 | 0.10 | 0.10 |
| Efficiency | |||||
| Asset turnover | 0.00 | 0.09 | 0.00 | 0.17 | 0.02 |
| Inventory turnover | - | - | - | - | - |
| Days sales outstanding | - | - | - | 3d | 2d |
| Days inventory outstanding | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - |
| Valuation | |||||
| P / E | - | - | - | - | - |
| P / B | - | - | - | - | - |
| P / S | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - |
| Growth | |||||
| Revenue growth (YoY) | -100.0% | 1766.5% | -98.2% | 827.3% | - |
| Revenue CAGR (3y) | - | 45.9% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - |
| Operating income growth (YoY) | -3.8% | 19.0% | -1976.6% | 79.8% | - |
| Net income growth (YoY) | -8.8% | 16.7% | - | - | - |
| EPS growth (YoY) | -5.8% | 18.8% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - |
| FCF growth (YoY) | -61.0% | 47.0% | -173.9% | -81.7% | - |
| FCF CAGR (5y) | - | - | - | - | - |
| Book value growth (YoY) | -42.9% | -30.4% | -23.1% | -3.8% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-12-31.
Product / service
$14.97M totalLicense$14.97M · 100.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
-3.06
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Vaccitech plc against the 5 most active filers in the same SIC group.